Advertisement

Parkinson's disease mortality and socioeconomic status: New information from a Korean study

  • Hélio A.G. Teive
    Affiliations
    Movement Disorders Unit, Neurology Service, Internal Medicine Department, Hospital de Clínicas, Federal University of Paraná, Curitiba, PR, Brazil
    Search for articles by this author
  • Joohi Jimenez-Shahed
    Correspondence
    Corresponding author. Medical Director, Movement Disorders Neuromodulation & Brain Circuit Therapeutics, Icahn School of Medicine at Mount Sinai, 1000 10th Ave., Suite 10c, New York, NY, 10019, USA.
    Affiliations
    Bonnie and Tom Strauss Movement Disorders Center, Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Search for articles by this author
      Parkinson's disease (PD) is the second most common chronic, progressive, neurodegenerative disease after Alzheimer's disease. It affects approximately 4–10 million people worldwide, and is expected to double in prevalence by 2030 as a result of population aging [
      • Martinez-Martin P.
      • Macaulay D.
      • Jalundhwala Y.J.
      • Um F.
      • Ohashi E.
      • Marshall T.
      • Sail K.
      The long-term direct and indirect economic burden among Parkinson's Disease caregivers in the United States.
      ,
      • Kim Y.W.
      • et al.
      Effects of socioeconomic status on mortality after Parkinson's Disease: a nationwide population-based matched cohort study in Korean populations.
      ]. It is well recognized that both motor and non-motor symptom progression occurs as the disease evolves [
      • Santos-Garcia D.
      • de Deus Fonticoba T.
      • Suárez Castro E E.
      • et al.
      Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's Disease patients: results from the COPPADIS study cohort.
      ,
      • Kalia L.V.
      • Lang A.E.
      Parkinson disease in 2015: evolving basic, pathological and clinical concepts in PD.
      ]. The rate of PD progression, particularly in stages IV and V, is well known from the classic 1967 study by Hoehn and Yahr, complemented by the seminal work published by Kempster et al., in 2010 [
      • Hoehn M.M.
      • Yahr M.D.
      Parkinsonism: onset, progression and mortality.
      ,
      • Kempster P.A.
      • O'Sullivan S.S.
      • Holton J.L.
      • Revesz T.
      • Lees A.J.
      Relationships between age and late progression of Parkinson's disease: a clinic-pathological study.
      ]. This scenario is further complicated by the fact that symptoms in these stages are often levodopa refractory, and alternate therapeutic interventions are limited [
      • Kalia L.V.
      • Lang A.E.
      Parkinson disease in 2015: evolving basic, pathological and clinical concepts in PD.
      ]. In this context, the mortality rate and quality of death certification in patients with PD has been matched with controls and extensively studied in recent years, and other studies have assessed the direct and indirect burden of the disease and quality of life among patients and caregivers [
      • Martinez-Martin P.
      • Macaulay D.
      • Jalundhwala Y.J.
      • Um F.
      • Ohashi E.
      • Marshall T.
      • Sail K.
      The long-term direct and indirect economic burden among Parkinson's Disease caregivers in the United States.
      ,
      • Hobson P P.
      • Meara J.
      Mortality and quality of death certification in a cohort of patients with Parkinson's Disease and matched controls in North Wales, UK at 18 years: a community-based cohort study.
      ,
      • Moscovich M.M.
      • Boschetti G.
      • Moro A.
      • Teive H.A.G.
      • Hassan A.
      • Munhoz R.P.
      Death certificate data and causes of death in patients with parkinsonism.
      ,
      • Kadastik-Eerme L.
      • Taba N.
      • Asser T.
      • Taba P.
      Incidence and mortality of Parkinson's Disease in Estonia.
      ,
      • Findley L.J.
      The economic impact of Parkinson's disease.
      ,
      • Rocca W.A.
      The future burden of Parkinson's Disease.
      ]. The economic impact of PD progression has raised significant concerns for patients themselves, for society, and for healthcare systems around the world [
      • Findley L.J.
      The economic impact of Parkinson's disease.
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Parkinsonism & Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Martinez-Martin P.
        • Macaulay D.
        • Jalundhwala Y.J.
        • Um F.
        • Ohashi E.
        • Marshall T.
        • Sail K.
        The long-term direct and indirect economic burden among Parkinson's Disease caregivers in the United States.
        Mov. Disord. 2019; 34: 236-245
        • Kim Y.W.
        • et al.
        Effects of socioeconomic status on mortality after Parkinson's Disease: a nationwide population-based matched cohort study in Korean populations.
        Park. Relat. Disord. 2020;
        • Santos-Garcia D.
        • de Deus Fonticoba T.
        • Suárez Castro E E.
        • et al.
        Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's Disease patients: results from the COPPADIS study cohort.
        Park. Relat. Disord. 2019; 66: 151-157
        • Kalia L.V.
        • Lang A.E.
        Parkinson disease in 2015: evolving basic, pathological and clinical concepts in PD.
        Nat. Rev. Neurol. 2016; 12: 65-66
        • Hoehn M.M.
        • Yahr M.D.
        Parkinsonism: onset, progression and mortality.
        Neurology. 1967; 17: 427-442
        • Kempster P.A.
        • O'Sullivan S.S.
        • Holton J.L.
        • Revesz T.
        • Lees A.J.
        Relationships between age and late progression of Parkinson's disease: a clinic-pathological study.
        Brain. 2010; 133: 1755-1762
        • Hobson P P.
        • Meara J.
        Mortality and quality of death certification in a cohort of patients with Parkinson's Disease and matched controls in North Wales, UK at 18 years: a community-based cohort study.
        BMJ Open. 2018; 8e018969https://doi.org/10.1136/bmjopen-2017-018969
        • Moscovich M.M.
        • Boschetti G.
        • Moro A.
        • Teive H.A.G.
        • Hassan A.
        • Munhoz R.P.
        Death certificate data and causes of death in patients with parkinsonism.
        Park. Relat. Disord. 2019; 41: 99-103
        • Kadastik-Eerme L.
        • Taba N.
        • Asser T.
        • Taba P.
        Incidence and mortality of Parkinson's Disease in Estonia.
        Neuroepidemiology. 2019; 53: 63-72
        • Findley L.J.
        The economic impact of Parkinson's disease.
        Park. Relat. Disord. 2007; 13: S8-S12
        • Rocca W.A.
        The future burden of Parkinson's Disease.
        Mov. Disord. 2019; 33: 8-9
        • Saadi A.
        • Himmelstein D.U.
        • Woolhandler S.
        • Mejia N.I.
        Racial disparities in neurologic health care access and utilization in the United States.
        Neurology. 2017; 88 (Epub 2017 May 17): 2268-2275https://doi.org/10.1212/WNL.0000000000004025
        • Hemming J.P.
        • Gruber-Baldini A.L.
        • Anderson K.E.
        • Fishman P.S.
        • Reich S.G.
        • Weiner W.J.
        • Shulman L.M.
        Arch. Neurol. 2011; 68 (Epub 2010 Dec 13. PMID: 21149802): 498-503https://doi.org/10.1001/archneurol.2010.326
        • Willis A.W.
        • Schootman M.
        • Kung N.
        • Evanoff B.A.
        • Perlmutter J.S.
        • Racette B.A.
        Predictors of survival in patients with Parkinson disease.
        Arch. Neurol. 2012; 69 (PMID: 22213411 Free PMC article): 601-607https://doi.org/10.1001/archneurol.2011.2370
        • Jennum P.
        • Zoetmulder M.
        • Korbo L.
        • Kjellberg J.
        The health-related, social, and economic consequences of parkinsonism: a controlled national study.
        J. Neurol. 2011; 258 (Epub 2011 Mar 11. PMID: 21394491): 1497-1506https://doi.org/10.1007/s00415-011-5969-1
        • Allyson Jones C.
        • Wayne Martin W.R.
        • Wieler M.
        • King-Jesso P.
        • Voaklander D.C.
        Incidence and mortality of Parkinson's disease in older Canadians.
        Park. Relat. Disord. 2012; 18 (Epub 2011 Dec 24. PMID: 22197034): 327-331https://doi.org/10.1016/j.parkreldis.2011.11.018
        • Peretz C.
        • Rozani V.
        • Giladi N.
        • El-Ad B.
        • Tsamir J.
        • Hemo B.
        • Gurevich T.
        The modifying effect of age on survival in Parkinson's disease: a population-based cohort study.
        Neuroepidemiology. 2019; 53: 13-19
        • Mackenbach J.P.
        • Stirbu I.
        • Roskam A.J.
        • Schaap M.M.
        • Menvielle G.
        • Leinsalu M.
        • Kunst A.E.
        European union working group on socioeconomic inequalities in health. Socioeconomic inequalities in health in 22 European countries.
        N. Engl. J. Med. 2008; 358 (PMID: 18525043): 2468-2481https://doi.org/10.1056/NEJMsa0707519
        • Pedro-Cuesta J.D.
        • Rodríguez-Farré E.
        • Lopez-Abente G.
        Spatial distribution of Parkinson's disease mortality in Spain, 1989-1998, as a guide for focused aetiological research or health-care intervention.
        BMC Publ. Health. 2009; 9: 445https://doi.org/10.1186/1471-2458-9-445